Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: Systematic review and economic model

Age and Ageing

Volumn 42, Issue 1, 2013, Pages 14-20

  Hyde, Christopher ^a   Peters, Jaime ^a   Bond, Mary ^a   Rogers, Gabriel ^a   Hoyle, Martin ^a   Anderson, Rob ^a   Jeffreys, Mike ^b   Davis, Sarah ^c   Thokala, Praveen ^c   Moxham, Tiffany ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Alzheimer's disease; Donepezil; Galantamine; Memantine; Older people; Rivastigmine; Systematic review

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EVIDENCE BASED PRACTICE; HEALTH STATUS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; MEMANTINE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84871341948     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afs165     Document Type: Article

References (30)

1. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975; 12: 189-98.
2. British National Formulary. BNF 57. March 2009. London: BMJ Group and RPS Publishing, 2009.
3. Knapp M, Prince M, Albanese E et al. Dementia UK: the full report. London: Alzheimer's Society, 2007.
4. National Institute of Health and Clinical Excellence. Donepezil, Galantamine, Rivastigmine (review) and Memantine for the Treatment of Alzheimer's Disease (Amended). NICE Technology Appraisal Guidance 111. London: NICE, 2009.
5. National Institute of Health and Clinical Excellence. Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease. NICE Technology Appraisal Guidance 217. 2009. London: NICE, 2011.
6. http://www.dailymail.co.uk/health/article-1348119/Banned- Alzheimers-drugs-available-TODAY-thanks-Mail-campaign.html (20 July 2011, date last accessed).
7. Bond M, Rogers G, Peters J et al. The effectiveness and costeffectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model. Health Technol Assess 2012; 16: 1-470.
8. Loveman E, Green C, Kirby J et al. The clinical and costeffectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006; 10: 1-160.
9. Gauthier S, Bodick N, Erzigkeit E et al. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11(Suppl 3): 6-7.
10. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002; 181: 36-42.
11. Brodaty H, Corey-Bloom J, Potocnik FCV, Truyen L, Gold M, Damaraju CRV. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatric Cogn Disord 2005; 20: 120-32.
12. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006; 174: 1099-105.
13. Bullock R, Erkinjuntti T, Lilienfeld S. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-Month treatment with galantamine. Dement Geriatric Cogn Disord 2004; 17: 29-34.
14. Feldman HH, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1056-63.
15. Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2007; 27: 484-7.
16. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
17. Van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 136-43.
18. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
19. Lopez-Bastida J, Hart W, Garcia-Perez L, Linertova R. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. J Alzheimers Dis 2009; 16: 399-407.
20. Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2007; 257: 330-6.
21. Brennan A, Nagy B, Brandtmuller A, Thomas SK, Sullivan SD, Akehurst R. The cost-utility of exelon patch in the management of patients with moderate Alzheimer's disease in the United Kingdom. Value Health 2007; 10: A384.
22. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 2005; 3: 77-86.
23. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007; 52: 519-26.
24. NHS Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Healthcare. York: CRD University of York, 2009.
25. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Clinical Excellence, 2008.
26. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practice: modeling studies. Value Health 2003; 6: 9-17.
27. http://www.nice.org.uk/guidance/index.jsp?action=download&o= 47048 (20 July 2011, date last accessed).
28. Getsios D, Blume S, Ishak KJ, MacLaine G. Cost-effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 2010; 28: 411-27.
29. Feldman H, Gauthier S, Hecker J et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 2004; 63: 644-50.
30. Suh GH, Jung HY, Lee CU, Choi S. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study. J Korean Med Sci 2008; 23: 10-7.